



**Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) in preclinical models of Acute Myeloid Leukemia (AML) at the 2019 AACR-NCI-EORTC Conference**

La Chaux-de-Fonds, Switzerland, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations of RP7214, a novel small molecule inhibitor of DHODH in preclinical models of Acute Myeloid Leukemia (AML).

**Highlights from the two posters include:**

- *RP7214 is a potent and novel DHODH inhibitor in AML acting via suppression of cellular pyrimidine pools and promoting differentiation to fully mature cells*
- *RP7214 demonstrated single-agent activity in AML cell lines and anti-tumor activities in both tumor size and tumor weight in MV-4-11 human leukemia xenograft model*
- *RP7214 potentiated the activity of gilteritinib (XOSPATA®) in reducing cell growth, induction of apoptosis, cell cycle arrest and inhibition of pAkt and pErk 1/2*
- *RP7214 demonstrated anti-tumor activities manifested by a reduction in both tumor size and tumor weight in MV-4-11 human leukemia xenograft model when combined with cytarabine (ARA-C)*

**About RP7214:**

RP7214 is a novel oral small molecule inhibitor of dihydroorotate dehydrogenase (DHODH) with demonstrated preclinical activity in myeloid malignancies and solid tumors. The compound is currently being evaluated in IND-enabling tolerability studies with a Phase I clinical trial in Myeloid Malignancies expected to commence in 2020.

**Details of the poster presentations:**

**-- Poster Title: Inhibition of Dihydroorotate Dehydrogenase (DHODH) by RP7214 attenuates growth and promotes differentiation of AML cell lines**

- |                       |                                 |
|-----------------------|---------------------------------|
| • Session Title:      | Therapeutic Agents: Other       |
| • Session Date:       | Tuesday, October 29, 2019       |
| • Session Start Time: | 12:30                           |
| • Session End Time:   | 16:00                           |
| • Location:           | Hall D, Hynes Convention Center |

- Permanent Abstract No.: C042

**-- Poster Title: RP7214, a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), potentiates activity of Gilteritinib and Cytarabine in preclinical models of AML**

- Session Title: Therapeutic Agents: Other
- Session Date: Tuesday, October 29, 2019
- Session Start Time: 12:30
- Session End Time: 16:00
- Location: Hall D, Hynes Convention Center
- Permanent Abstract No.: C044

**About Rhizen Pharmaceuticals S.A.:**

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen's website, [www.rhizen.com](http://www.rhizen.com).

**Contact:**

Kumar V. Penmetsa, Ph.D.  
Executive Vice President, Corporate Development  
Rhizen Pharmaceuticals S.A.  
Telephone: +1-267-207-5707  
Email: [kvp@rhizen.com](mailto:kvp@rhizen.com)